Cite
HARVARD Citation
Carducci, M. et al. (n.d.). 4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC). European journal of cancer. pp. S713-S714. [Online].